Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)

Pancreatic Adenocarcinoma Clinical Trial

Official title:

An Open Label, Phase II Study of Chemotherapy + Anakinra in Patients With Resectable, Locally Advanced or Potentially Resectable Pancreatic Adenocarcinoma (PDAC)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04926467
• Other study ID #: 020-476
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: June 2021
• Est. completion date: June 2026

Study information

• Verified date: June 2021
• Source: Baylor Research Institute
• Contact: Heather Williams, MS
• Phone: (214) 818-7879
• Email: Heather.Williams1[@]BSWHealth.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Based on a central role of inflammation in pancreas cancer, the role of IL 1 in acute and chronic inflammation , the inhibitory effect of IL 1 alfa and beta by anakinra and preliminary experience with anakinra in combination with chemotherapy in metastasis (with FOLFIRINOX) and localized disease (with gemcitabine/abraxane/cisplatin), a phase 2 study with anakinra in combination with perioperative chemotherapy for patients with PDAC is being proposed.

Description:

This is an open-label, single-arm, prospective phase II study conducted by Baylor Scott and White Research Institute in Dallas.

The study will enroll patients with pancreatic adenocarcinoma that are planned to receive pre-operative chemotherapy followed by surgical resection and post operative treatment. Local surgical/biopsy and pathology reports will constitute adequate documentation of histology/cytology for study inclusion.

Patients will receive pre- and post-operative chemotherapy plus Anakinra. Specifically, the pre-operative chemotherapy regimen will be a combination of Nab-paclitaxel, gemcitabine and cisplatin, while post-operative chemotherapy will use 5-Fluorouracil, oxaliplatin, and irinotecan. Patients will also receive growth factor (Neupogen followed by Neulasta) for safety and to ensure that treatment is not delayed due to neutropenic effects of chemotherapy.

Anakinra will be self-administered by the participants through out the treatment period. A treatment break of 2 days will be given prior to the surgery day.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 24
• Est. completion date: June 2026
• Est. primary completion date: June 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• A patient will be eligible for inclusion in this study if he or she meets all of the following criteria:

1. 18 years of age or older

2. Histologically or Cytologically confirmed pancreatic ductal adenocarcinoma. Mixed subtypes of adenocarcinoma are acceptable as long as majority of cells are ductal adenocarcinoma.

3. Resectable, locally advanced or potentially resectable pancreatic adenocarcinoma

4. American Joint Committee on Cancer (AJCC) Stage I-III Pancreatic carcinoma.

5. Patient has Eastern Cooperative Oncology Group( ECOG ) Performance Status 0 to 1

6. Serum albumin =2.0 g/dL.

7. Adequate hematologic function as defined by:

1. Absolute neutrophil count (ANC) =1500/mm3;

2. Platelets =70,000 x 10^3/µl;

3. Hemoglobin =9 g/dL (in the absence of red blood transfusion).

8. Adequate liver function, as defined by:

1. Serum total bilirubin =2 x ULN mg/dL, prior to initiation of treatment.

2. ALT (SGPT) and AST (SGOT) =2.5 x upper limit of normal (ULN).

9. Adequate renal function, as defined by serum creatinine= 1.5 x ULN, or creatinine clearance =50 mL/min

10. Women of child bearing potential and men must agree to use contraception throughout the study and for one month after the last anakinra administration.

11. Subjects must understand and sign the informed consent form

12. Patients must be accessible for treatment and follow-up.

Exclusion Criteria:

• A patient will be ineligible for inclusion in this study if he or she meets any of the following criteria:

1. <18 years of age

2. History of organ transplant.

3. Patients with islet cell neoplasms

4. Patients with stage IV pancreatic carcinoma

5. Active, uncontrolled bacterial, viral, or fungal infection(s) requiring systemic therapy

6. Known active infection with hepatitis B or hepatitis C

7. Presence of clinically significant cirrhosis as determined by the investigator

8. Known HIV positive status.

9. Current, active immunosuppressive therapy such as cyclosporine, tacrolimus, etc.

10. Major surgery or vascular device placement within 2 weeks prior to Day 1 of treatment in study

11. Prior chemotherapy or radiation for pancreatic cancer

12. History of allergy or hypersensitivity to the study drugs

13. Patient is enrolled in any outside therapeutic clinical protocol or investigational trial with an investigational drug within 5 half-lives prior to Study ID assignment

14. Previous or current treatment with anakinra, canakinumab or any other IL-1 inhibitor

15. Other malignancy within five years(except cutaneous, non-melanoma malignancies or cervical carcinoma in site), unless the probability of recurrence of the prior malignancy is <5% as determined by the Principal Investigator based on available information.

16. Significant cardiac disease (uncontrolled congestive heart failure (CHF), myocardial infarction or significant ventricular arrhythmias) within the last six months.

17. Other severe and/or uncontrolled medical conditions (e.g: prior gastrointestinal (GI) disease or history of prior pelvic or abdominal radiation) or other conditions deemed by investigator as unsuitable for participation/enrollment

18. Peripheral sensory neuropathy > or equal to grade 2 at baseline

19. Abnormal liver function tests as follows:

1. Total bilirubin of > 2 x ULN

2. AST or ALT > 5x ULN

20. Serum albumin ? 2.0 g/dL.

21. Abnormal hematologic function as follows :

1. Absolute neutrophil count (ANC) ? 1500/mm3;

2. Platelets ? 70,000 x 10^3/µl;

3. Hemoglobin ? 9 g/dL (in the absence of red blood transfusion).

22. Pregnant or nursing women

23. No signed Informed consent form

Related Conditions & MeSH terms

• Adenocarcinoma
• Pancreatic Adenocarcinoma

Intervention

Drug:
• Anakinra
Pre-operative treatment: Nab-paclitaxel (125 mg/m2), gemcitabine (1000 mg/m2), and cisplatin (25 mg/m2) will be given on Day 1 and 8 of a 21-day cycle. Patients will receive anakinra 100 mg injection twice a day starting on day 1 of chemotherapy. Anakinra will be self-administered by the patients and will be discontinued 2 days prior to surgery. Total number of cycles = 4. Post-operative treatment: 5-Fluorouracil (2400 mg/m2 CI for 48 hours), oxaliplatin (85 mg/m2), and irinotecan (150 mg/m2) will be given once every 2 weeks (1 cycle =14 days). Patients will receive anakinra 100 mg injection subcutaneously twice a day starting on day 1 of chemotherapy (initiated within 4-8 weeks after surgery). Anakinra will be self-administered by the patient throughout the treatment without any break. Total number of cycles = 8.

Locations

Country	Name	City	State
United States	Baylor University Medical Center, Charles A Sammons Cancer Center	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Baylor Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the percentage of patients that have a normalization of CA19-9 after pre-op treatment with the combination of nab-paclitaxel (abraxane), gemcitabine, cisplatin and anakinra.		24 months
Secondary	To determine the effect of anakinra in combination with perioperative chemotherapy on overall survival (OS) of PDAC patients. A benchmark of 24 months OS will be used to determine how many patients meet or exceed this goal.		24 months
Secondary	To determine the effect of anakinra in combination with perioperative chemotherapy on the median disease free survival (DFS). A benchmark of 12 months DFS will be used to determine how many patients meet or exceed this goal.		12 months
Secondary	To determine the effect of anakinra in combination with perioperative chemotherapy on response rate		24 months
Secondary	To determine the R0 resection rates (complete tumor removal with negative resection margins) obtained with anakinra + pre-operative chemotherapy.		24 months
Secondary	To describe the effect of anakinra in combination with perioperative chemotherapy on the prevalence and severity of pain by monitoring patients' pain level using memorial pain assessment card (MPAC).		24 months
Secondary	To determine the effect of anakinra in combination with perioperative chemotherapy on patients' health-related quality of life by monitoring patients using EORTC quality of life survey questionnaire (EORTC QLQ-C30).		24 months
Secondary	To determine the effect of anakinra in combination with perioperative chemotherapy on the inflammasomes ( IL6, CRP, IL1a and IL1ß) in blood and in the resected pathology specimens.		24 months